Related Experiment Video

Updated: Jul 5, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

The development of targeted therapies in rheumatoid arthritis

Edward M Vital1, Paul Emery

  • 1Academic Section of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.

Journal of Autoimmunity
|May 27, 2008
PubMed

Insights

Rheumatoid arthritis therapy has advanced through cellular and molecular insights, but clinical trials often yield unexpected results. Successful treatments require close collaboration between clinical and laboratory research.

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) therapy has significantly advanced due to improved understanding of cellular and molecular disease mechanisms.
  • Targeting specific disease mediators has been a key focus in developing novel RA treatments.

Purpose of the Study:

  • To review key stages in the development of rheumatoid arthritis therapeutic agents.
  • To highlight the challenges and successes in translating in vitro and animal model findings to clinical trials.
  • To discuss remaining unanswered questions in RA therapeutic development.

Main Methods:

  • Review of scientific literature on rheumatoid arthritis therapies.
  • Analysis of clinical trial outcomes for targeted agents.
  • Examination of the interplay between laboratory research and clinical application.

Main Results:

  • Proposed therapeutic targets like cytokines, chemokines, T cell receptor trimolecular complex, T cells, and B cells have shown variable clinical success.
  • Unexpected outcomes in clinical trials underscore the complexity of translating preclinical findings.
  • Successful RA therapeutic strategies often emerge from a synergistic dialogue between clinical observations and laboratory investigations.

Conclusions:

  • The development of RA therapies is an evolving process requiring continuous integration of basic science and clinical practice.
  • Further research is needed to address the complexities of RA pathogenesis and optimize targeted treatment strategies.
  • A collaborative approach remains crucial for advancing rheumatoid arthritis treatment and improving patient outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...